Iovance Biotherapeutics
World Rank (Jan-05-2024)
5,548
Market Cap (Jan-05-2024)
2.075 Billion USD
World Rank (Jul-30-2023)
6,175
Market Cap (Jul-30-2023)
1.782 Billion USD
World Rank (Dec-25-2022)
8,549
Market Cap (Dec-25-2022)
0.966 Billion USD
World Rank (Jan-07-2022)
5,413
Market Cap (Jan-07-2022)
2.55 Billion USD
Annual Revenue in USD
0 Million USD
Annual Net Income in USD
-395 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Company Profile
Iovance Biotherapeutics is a development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes company. The headquarters is in USA.
Company Website